This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
electroCore (ECOR) delivered earnings and revenue surprises of -9.38% and +0.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
by Zacks Equity Research
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
by Zacks Equity Research
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 80.3% in Perspective Therapeutics (CATX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Perspective Therapeutics (CATX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Perspective Therapeutics (CATX) have performed compared to their sector so far this year.
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Perspective Therapeutics (CATX) delivered earnings and revenue surprises of -33.33% and 20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of -3.70% and 6.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.28% and 9.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?